38 mins. ago
Multiple outlets in Italy are reporting that Juventus and Turkish Super Lig club Besiktas are in direct negotiations over a potential deal for midfielder Fabio Miretti and that the two sides are currently discussing the 'formula' of the transfer.
Juventus have already added Randal Kolo Muani, Kerim Alajbegovic, Guglielmo Vicario, Jhon Lucumi, Jeff Ekhator and Zeki Celik to their ranks this summer but are still hoping to add a few more signings to the list before the close of the transfer window.
"In general we've had a good transfer market, some areas need a few cosmetic changes, others entire restoration projects," said head coach Luciano Spalletti during a press conference on Saturday.
In order for those new signings to come in, other players must first be sold, and according to the latest updates, Miretti could be one of those players that ends up on the chopping block.
According to reports from various sources on Sunday including Sky Sport Italia's Gianluca Di Marzio, Juventus are in direct discussions with Besiktas to discuss the sale of Miretti.
#juventus #according #italy
Juventus have already added Randal Kolo Muani, Kerim Alajbegovic, Guglielmo Vicario, Jhon Lucumi, Jeff Ekhator and Zeki Celik to their ranks this summer but are still hoping to add a few more signings to the list before the close of the transfer window.
"In general we've had a good transfer market, some areas need a few cosmetic changes, others entire restoration projects," said head coach Luciano Spalletti during a press conference on Saturday.
In order for those new signings to come in, other players must first be sold, and according to the latest updates, Miretti could be one of those players that ends up on the chopping block.
According to reports from various sources on Sunday including Sky Sport Italia's Gianluca Di Marzio, Juventus are in direct discussions with Besiktas to discuss the sale of Miretti.
#juventus #according #italy
1 hr. ago
"Please, boys. Don't make my final years a misery." The words of the future King Charles III as he pleaded with his two sons to patch things up at their grandfather's funeral in April 2021 have just acquired a whole new resonance.
The "boys", better known as Prince William and Prince Harry, never did make up. Indeed, their feud only darkened and deepened as the elder brother fumed at the younger's treachery towards the Royal family in general, and his wife, in particular. (Outrageously, in her interview with Oprah, Meghan accused unnamed members of the family of racism in relation to her unborn baby's skin colour.)
The last time Harry and William stood together, just the two of them, was in July 2021 at the unveiling of a bronze statue of their late mother on what would have been her 60th birthday. The pair could barely look at each other. For William, Harry's deeply personal and spiteful revelations two years later in his biography, Spare, were an unimaginable betrayal by the human being he once trusted best.
The last time the two brothers were together was in 2021, at the unveiling of a bronze statue of their late mother - Dominic Lipinski/AFP
A lid could be kept on that seething Shakespearean sibling rivalry, as long as Diana's beloved boys, now men in their 40s, were separated by an ocean. Harry and Meghan found freedom in California from the stultifying Windsor ways they so publicly scorned. The Waleses were left to steady the ship after the turbulence of "Megxit". They did so admirably and to universal acclaim despite Princess Catherine's shocking brush with cancer.
#william #harry #make
The "boys", better known as Prince William and Prince Harry, never did make up. Indeed, their feud only darkened and deepened as the elder brother fumed at the younger's treachery towards the Royal family in general, and his wife, in particular. (Outrageously, in her interview with Oprah, Meghan accused unnamed members of the family of racism in relation to her unborn baby's skin colour.)
The last time Harry and William stood together, just the two of them, was in July 2021 at the unveiling of a bronze statue of their late mother on what would have been her 60th birthday. The pair could barely look at each other. For William, Harry's deeply personal and spiteful revelations two years later in his biography, Spare, were an unimaginable betrayal by the human being he once trusted best.
The last time the two brothers were together was in 2021, at the unveiling of a bronze statue of their late mother - Dominic Lipinski/AFP
A lid could be kept on that seething Shakespearean sibling rivalry, as long as Diana's beloved boys, now men in their 40s, were separated by an ocean. Harry and Meghan found freedom in California from the stultifying Windsor ways they so publicly scorned. The Waleses were left to steady the ship after the turbulence of "Megxit". They did so admirably and to universal acclaim despite Princess Catherine's shocking brush with cancer.
#william #harry #make
2 hours ago
Some offers on this page are from advertisers who pay us, which may affect which products we write about, but not our recommendations. See our Advertiser Disclosure.
Find out how much you could earn by locking in a high CD rate today. The Federal Reserve cut its federal funds rate three times in 2025. So far in 2026, the Fed has left interest rates alone, and so now could be your last chance to lock in a competitive CD rate before rates move further. CD rates vary widely across financial institutions, so it's important to ensure you're getting the best rate possible when shopping around for a CD.
The following is a breakdown of CD rates today and where to find the best offers.
Generally, the best CD rates today are offered on shorter terms of around one year or less. Online banks and credit unions, in particular, offer the top CD rates.
Today, Saturday, August 22, 2026, the highest CD rate is 4.35%. This rate is offered by Sallie Mae on its 3-year CD.
#rate #rates #best #around
Find out how much you could earn by locking in a high CD rate today. The Federal Reserve cut its federal funds rate three times in 2025. So far in 2026, the Fed has left interest rates alone, and so now could be your last chance to lock in a competitive CD rate before rates move further. CD rates vary widely across financial institutions, so it's important to ensure you're getting the best rate possible when shopping around for a CD.
The following is a breakdown of CD rates today and where to find the best offers.
Generally, the best CD rates today are offered on shorter terms of around one year or less. Online banks and credit unions, in particular, offer the top CD rates.
Today, Saturday, August 22, 2026, the highest CD rate is 4.35%. This rate is offered by Sallie Mae on its 3-year CD.
#rate #rates #best #around
2 hours ago
Attorney General Todd Blanche praised the Justice Department's $400 million settlement with TikTok over allegations of children's privacy violations, saying the deal is a "fair, just and right result."
Speaking on "Saturday in America," Blanche said the deal addresses TikTok's past actions while helping protect children online.
"If companies and entities are not doing what they're supposed to do to make sure that happens, we're [going to] come after them," Blanche told host Kayleigh McEnany.
Trump Says He Will Nominate Acting Ag Todd Blanche To Permanently Lead Justice Department
Attorney General Todd Blanche listens during a news conference at the Justice Department Aug. 12, 2026, in Washington, D.C.
#blanche #todd #TikTok #speaking
Speaking on "Saturday in America," Blanche said the deal addresses TikTok's past actions while helping protect children online.
"If companies and entities are not doing what they're supposed to do to make sure that happens, we're [going to] come after them," Blanche told host Kayleigh McEnany.
Trump Says He Will Nominate Acting Ag Todd Blanche To Permanently Lead Justice Department
Attorney General Todd Blanche listens during a news conference at the Justice Department Aug. 12, 2026, in Washington, D.C.
#blanche #todd #TikTok #speaking
2 hours ago
Yuki Tsunoda says Racing Bulls has been "pretty impressed" with the way he has adapted to Formula 1's 2026-spec machinery as he stands in for Liam Lawson at the Dutch Grand Prix.
Lawson got a call-up to Red Bull after Isack Hadjar injured his wrist over the summer break, hence Tsunoda's opportunity at Racing Bulls on a tricky sprint weekend in Zandvoort.
The 26-year-old was unfamiliar with the new generation of cars but has been getting closer and closer to impressive rookie team-mate Arvid Lindblad.
Tsunoda was 0.825s adrift of the Briton in the only free practice session, but brought his deficit down to 0.433s in SQ1 and 0.360s in SQ2, then 0.011s in Q1 and 0.102s in Q2, having finished the sprint race 11.5 seconds in arrears.
"Honestly, I'm super happy," the ***** anese racer rejoiced. "Certainly, I enjoyed so much this qualifying.
#closer #yuki #formula
Lawson got a call-up to Red Bull after Isack Hadjar injured his wrist over the summer break, hence Tsunoda's opportunity at Racing Bulls on a tricky sprint weekend in Zandvoort.
The 26-year-old was unfamiliar with the new generation of cars but has been getting closer and closer to impressive rookie team-mate Arvid Lindblad.
Tsunoda was 0.825s adrift of the Briton in the only free practice session, but brought his deficit down to 0.433s in SQ1 and 0.360s in SQ2, then 0.011s in Q1 and 0.102s in Q2, having finished the sprint race 11.5 seconds in arrears.
"Honestly, I'm super happy," the ***** anese racer rejoiced. "Certainly, I enjoyed so much this qualifying.
#closer #yuki #formula
3 hours ago
LAFC didn't get the three points it wanted (and probably deserved) on Saturday night at BMO Stadium, settling for a 1-1 draw with the Portland Timbers. Looking beyond the final score, however, there was a product on the pitch that should leave Black & Gold supporters more optimistic than they've been in weeks.
For the majority of the month, LAFC's attack had simply gone quiet. What started as a scoring outburst following a return from the World Cup, with 10 goals scored across three matches, quickly dried up as August arrived. A pair of consecutive 1-0 defeats at the hands of San Diego FC and Colorado Rapids preceded Saturday's match, following a stretch that saw LA play four straight one-goal games across all competitions.
The eye test certainly matched the box score, with chances harder to come by and failing to find the net when they did arrive.
Saturday told a different story, despite Portland's David Da Costa pouncing on an early fast-break opportunity just four minutes in to put the visitors ahead. Rather than wilting away, LAFC spent the remainder of the evening generating the kind of pressure that had been missing.
"We pushed all game," head coach Marc Dos Santos said. "When you concede like that early, you can have so many doubts in your head...I have nothing to point out to the players. What I told the guys after the game is that if we show up like that in every game, we're going to win a lot of games."
#lafc
For the majority of the month, LAFC's attack had simply gone quiet. What started as a scoring outburst following a return from the World Cup, with 10 goals scored across three matches, quickly dried up as August arrived. A pair of consecutive 1-0 defeats at the hands of San Diego FC and Colorado Rapids preceded Saturday's match, following a stretch that saw LA play four straight one-goal games across all competitions.
The eye test certainly matched the box score, with chances harder to come by and failing to find the net when they did arrive.
Saturday told a different story, despite Portland's David Da Costa pouncing on an early fast-break opportunity just four minutes in to put the visitors ahead. Rather than wilting away, LAFC spent the remainder of the evening generating the kind of pressure that had been missing.
"We pushed all game," head coach Marc Dos Santos said. "When you concede like that early, you can have so many doubts in your head...I have nothing to point out to the players. What I told the guys after the game is that if we show up like that in every game, we're going to win a lot of games."
#lafc
3 hours ago
It has been a while since the Rodri saga between Barcelona and Real Madrid ended once and for all.
Los Blancos looked favourites to sign him from the start of the summer, but the Catalan club leapfrogged them and secured the player's signature.
Rodri has since been unveiled as a Barça player and, ideally, everyone should have moved on from whatever happened before.
However, the Spaniard's decision to join Barcelona instead of Madrid continues to generate reactions from the Spanish capital.
Speaking in the mixed zone after the Espanyol game (h/t Diario AS), Madrid goalkeeper Thibaut Courtois was asked about Rodri and offered a rather blunt response.
#Barcelona #blancos #however
Los Blancos looked favourites to sign him from the start of the summer, but the Catalan club leapfrogged them and secured the player's signature.
Rodri has since been unveiled as a Barça player and, ideally, everyone should have moved on from whatever happened before.
However, the Spaniard's decision to join Barcelona instead of Madrid continues to generate reactions from the Spanish capital.
Speaking in the mixed zone after the Espanyol game (h/t Diario AS), Madrid goalkeeper Thibaut Courtois was asked about Rodri and offered a rather blunt response.
#Barcelona #blancos #however
3 hours ago
The Washington Commanders' offseason has seen quite a few shifts. New faces have been brought in on both sides of the ball, and while general manager Adam Peters spent a lot of time and money on defense, he didn't neglect the offense, eventually signing wide receiver Stefon Diggs to give Jayden Daniels more offensive weapons.
One of the questions around the Commanders' offense is regarding the offensive line. Starting left tackle Laremy Tunsil suffered a torn triceps muscle during camp and is out for the remainder of the season shortly after signing a massive extension. Center Nick Allegretti finally returned to the practice field after missing time with a calf strain.
Sports Illustrated Senior NFL writer Albert Breer recently discussed what he's seen from the Commanders' offensive line during training camp. After talking about Tunsil's injury, Breer writes:
The staff briefly considered moving Josh Conerly Jr. back to his college position, but decided against it because they really liked his progress at right tackle, having gotten bigger and stronger. Plus, they didn't want him to have to rewire everything for this year and then go back to the right side next year. So, Brandon Coleman will be at left tackle, as he was as a rookie in 2024, which means Chris Paul will be the left guard. The other question is at center, where veteran Nick Allegretti, who's got high-end football IQ and is steady, is trying to hold off Julian Good-Jones and rookie Matt Gulbin. Also worth noting: Right guard Sam Cosmi might be the team's best lineman through camp, coming back from an injury-marred season last year.
The competition between Allegretti and Julian Good-Jones is probably not as close as Breer alludes to, but if it is, Peters may find himself in hot water for letting Tyler Biadasz go. The center-to-quarterback exchange has to be seamless. Any gaffes in that exchange will always result in a lost play and have a high likelihood of ending with a turnover. The more work Allegretti gets with Daniels, the smoother that exchange will be.
#Commanders #center #camp #back
One of the questions around the Commanders' offense is regarding the offensive line. Starting left tackle Laremy Tunsil suffered a torn triceps muscle during camp and is out for the remainder of the season shortly after signing a massive extension. Center Nick Allegretti finally returned to the practice field after missing time with a calf strain.
Sports Illustrated Senior NFL writer Albert Breer recently discussed what he's seen from the Commanders' offensive line during training camp. After talking about Tunsil's injury, Breer writes:
The staff briefly considered moving Josh Conerly Jr. back to his college position, but decided against it because they really liked his progress at right tackle, having gotten bigger and stronger. Plus, they didn't want him to have to rewire everything for this year and then go back to the right side next year. So, Brandon Coleman will be at left tackle, as he was as a rookie in 2024, which means Chris Paul will be the left guard. The other question is at center, where veteran Nick Allegretti, who's got high-end football IQ and is steady, is trying to hold off Julian Good-Jones and rookie Matt Gulbin. Also worth noting: Right guard Sam Cosmi might be the team's best lineman through camp, coming back from an injury-marred season last year.
The competition between Allegretti and Julian Good-Jones is probably not as close as Breer alludes to, but if it is, Peters may find himself in hot water for letting Tyler Biadasz go. The center-to-quarterback exchange has to be seamless. Any gaffes in that exchange will always result in a lost play and have a high likelihood of ending with a turnover. The more work Allegretti gets with Daniels, the smoother that exchange will be.
#Commanders #center #camp #back
4 hours ago
Benfica and Aston Villa have both made initial enquiries to sign Barcelona left-back Alejandro Balde, according to Diario SPORT. The 22-year-old has reportedly instructed his agent, Jorge Mendes, to find him a new club before the transfer window closes.
Hansi Flick and Deco do not consider Balde a priority, according to reporting relayed by Tribuna. Barcelona are prioritising João Cancelo's return to reinforce the backline. Balde's reduced priority and his willingness to consider a move have been reported as separate developments.
Joao Cancelo presents his FC Barcelona jersey during his official unveiling.
Benfica have submitted a proposal of around €20 million, with Barcelona's valuation expectations presenting an obstacle. The report says creative sell-on clauses would be required to bridge that gap.
Aston Villa remain interested in signing a top-class left-back, but any move for Balde is contingent on the club generating late transfer funds through player sales.
#benfica #aston
Hansi Flick and Deco do not consider Balde a priority, according to reporting relayed by Tribuna. Barcelona are prioritising João Cancelo's return to reinforce the backline. Balde's reduced priority and his willingness to consider a move have been reported as separate developments.
Joao Cancelo presents his FC Barcelona jersey during his official unveiling.
Benfica have submitted a proposal of around €20 million, with Barcelona's valuation expectations presenting an obstacle. The report says creative sell-on clauses would be required to bridge that gap.
Aston Villa remain interested in signing a top-class left-back, but any move for Balde is contingent on the club generating late transfer funds through player sales.
#benfica #aston
4 hours ago
Following Saturday's UFC Fight Night: Hernandez vs. Rodrigues event at Golden 1 Center in Sacramento, Calif., UFC CEO Dana White announced the recipients of the performance-bases bonuses.
Fight of the Night honors went to the main event. No. 7 ranked middleweight Anthony Hernandez and No. 10 ranked Gregory Rodrigues headlined the fight card and did not disappoint. Rodrigues won via unanimous decision but the match will likely be a Fight of the Year candidate. The back and forth war earned each an extra $100,000.
Banking the other two Performance of the Night awards were lightweight MarQuel Mederos and women's flyweight Carli Judice.
Mederos stopped Mason Jones in the second round via TKO due to elbows and punches. Judice scored a first-round finish over Jeisla Chaves in main card action. A front kick to the body set up fight-ending punches.
UFC Sacramento featured 13 bouts. 10 of them resulted in stoppages. The six other fighters that stopped their opponents received $25,000 finishing bonuses. 16,867 spectators were in attendance at Golden 1 Center generating $3.3 million is gate receipts.
#fight #night #hernandez #center
Fight of the Night honors went to the main event. No. 7 ranked middleweight Anthony Hernandez and No. 10 ranked Gregory Rodrigues headlined the fight card and did not disappoint. Rodrigues won via unanimous decision but the match will likely be a Fight of the Year candidate. The back and forth war earned each an extra $100,000.
Banking the other two Performance of the Night awards were lightweight MarQuel Mederos and women's flyweight Carli Judice.
Mederos stopped Mason Jones in the second round via TKO due to elbows and punches. Judice scored a first-round finish over Jeisla Chaves in main card action. A front kick to the body set up fight-ending punches.
UFC Sacramento featured 13 bouts. 10 of them resulted in stoppages. The six other fighters that stopped their opponents received $25,000 finishing bonuses. 16,867 spectators were in attendance at Golden 1 Center generating $3.3 million is gate receipts.
#fight #night #hernandez #center
4 hours ago
Kade Anderson made his major league debut on Saturday afternoon against the Chicago Cubs. (Photo by Eric Hiller/MLB Photos via Getty Images)
Kade Anderson, the third pick in the 2025 MLB draft, made his major league debut on Saturday afternoon in Seattle against the Chicago Cubs. He became the first player from that class to make it to the big leagues.
According to Keith Law of The Athletic, Anderson is number one prospect in baseball. There was much consternation about bringing him up from Double-A Arkansas. Anderson pitched two seasons at baseball juggernaut LSU, accruing a 16-3 record before entering the draft last year. Due his heavy workload helping the Tigers win their eighth national ****** le, Seattle elected to have him sit out the remainder of 2025 to avoid injury.
Anderson, a 6'2" lefty, skipped the lower levels of the minors and has spent the entire season at Double-A, where he went 10-1 with a 1.06 ERA, and struck out 135 batters vs. just 13 walks. A 10/1 strikeout to walk ratio will play in any league.
But, because Anderson is just one year out of college and has been in Double-A all season, he was not on Seattle's 40-man roster. That changed when the team elected to call him up. As a general matter, Anderson won't pitch in enough games this season to lose his rookie status for next year. However, because he is now on the 40-man roster, the Mariners will not be allowed to have any contact with him in the event there is a lockout come December 1st. And with a rookie getting his first taste of big league competition, with potentially many things to learn from and work on, Seattle — and Anderson — may find it quite problematic that they cannot communicate with each other for the duration of the lockout. It is impossible to know — especially at this early date — the impact that will have on the pitcher's development, but it is not an ideal situation. Had the Mariners kept Anderson on the farm for the whole year, they could have worked with him all winter, regardless of any labor dispute.
#anderson #league #Seattle #saturday
Kade Anderson, the third pick in the 2025 MLB draft, made his major league debut on Saturday afternoon in Seattle against the Chicago Cubs. He became the first player from that class to make it to the big leagues.
According to Keith Law of The Athletic, Anderson is number one prospect in baseball. There was much consternation about bringing him up from Double-A Arkansas. Anderson pitched two seasons at baseball juggernaut LSU, accruing a 16-3 record before entering the draft last year. Due his heavy workload helping the Tigers win their eighth national ****** le, Seattle elected to have him sit out the remainder of 2025 to avoid injury.
Anderson, a 6'2" lefty, skipped the lower levels of the minors and has spent the entire season at Double-A, where he went 10-1 with a 1.06 ERA, and struck out 135 batters vs. just 13 walks. A 10/1 strikeout to walk ratio will play in any league.
But, because Anderson is just one year out of college and has been in Double-A all season, he was not on Seattle's 40-man roster. That changed when the team elected to call him up. As a general matter, Anderson won't pitch in enough games this season to lose his rookie status for next year. However, because he is now on the 40-man roster, the Mariners will not be allowed to have any contact with him in the event there is a lockout come December 1st. And with a rookie getting his first taste of big league competition, with potentially many things to learn from and work on, Seattle — and Anderson — may find it quite problematic that they cannot communicate with each other for the duration of the lockout. It is impossible to know — especially at this early date — the impact that will have on the pitcher's development, but it is not an ideal situation. Had the Mariners kept Anderson on the farm for the whole year, they could have worked with him all winter, regardless of any labor dispute.
#anderson #league #Seattle #saturday
6 hours ago
Interested in OBOOK Holdings Inc.? Here are five stocks we like better.
OwlTing is shifting toward commercializing OwlPay, its stablecoin-enabled cross-border settlement platform. The company has approximately 80 signed enterprise relationships, but many remain in sales, integration or onboarding rather than generating production volume.
Management is targeting more than $1 billion in ******* ulative OwlPay payment volume in 2026, while emphasizing enterprise trade, treasury and liquidity-management flows. Visa Direct activity is expected to begin in the fourth quarter, with further expansion planned across ******* an, Taiwan and other regional markets.
First-half revenue was broadly flat at $3.87 million, while net loss widened to $18.82 million, partly due to $10.4 million in non-cash share-based compensation and $2.5 million in finance costs. The company ended June with $10.19 million in cash and cash equivalents and $1.67 million in restricted cash.
OBOOK (NASDAQ:OWLS), which operates under the OwlTing Group brand, said its first-half 2026 results reflected a transition from building stablecoin-enabled payments infrastructure to commercializing its OwlPay cross-border settlement platform.
#owlpay #owlting #commercializing
OwlTing is shifting toward commercializing OwlPay, its stablecoin-enabled cross-border settlement platform. The company has approximately 80 signed enterprise relationships, but many remain in sales, integration or onboarding rather than generating production volume.
Management is targeting more than $1 billion in ******* ulative OwlPay payment volume in 2026, while emphasizing enterprise trade, treasury and liquidity-management flows. Visa Direct activity is expected to begin in the fourth quarter, with further expansion planned across ******* an, Taiwan and other regional markets.
First-half revenue was broadly flat at $3.87 million, while net loss widened to $18.82 million, partly due to $10.4 million in non-cash share-based compensation and $2.5 million in finance costs. The company ended June with $10.19 million in cash and cash equivalents and $1.67 million in restricted cash.
OBOOK (NASDAQ:OWLS), which operates under the OwlTing Group brand, said its first-half 2026 results reflected a transition from building stablecoin-enabled payments infrastructure to commercializing its OwlPay cross-border settlement platform.
#owlpay #owlting #commercializing
6 hours ago
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has released topline results from the Phase 3 LUCIDITY trial of avexitide on August 18, 2026. Shares closed Monday down 0.9% at $21.43, then traded 15.7% higher at $24.80 after hours after the company scheduled the readout. The rally came before investors saw any efficacy or safety data, underscoring how much hope is attached to one event. For Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), the question is whether a successful metabolic-disease trial can finally replace the failed ALS narrative that has defined the company since Relyvrio was withdrawn.
LUCIDITY randomized 78 adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery in a 3:2 ratio to receive once-daily avexitide or placebo. The FDA-agreed primary outcome measures the reduction in the composite of Level 2 and Level 3 hypoglycemic events through Week 16. Avexitide is designed to block the exaggerated GLP-1 response that can drive excess insulin secretion and dangerous drops in blood glucose.
The trial is therefore more than another pipeline update. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) currently has no approved product, and avexitide is its most advanced near-term opportunity to rebuild a commercial business. A positive result would validate the company's move into endocrine disease. A miss would return attention to earlier-stage programs that cannot replace a late-stage **** et quickly.
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) enters the readout with supportive early evidence. Amylyx said five earlier Phase 1 and Phase 2 studies produced consistent signals. In a 28-day, open-label Phase 2b crossover study involving 16 patients who had undergone Roux-en-Y gastric bypass or other upper gastrointestinal surgeries, the 90 mg once-daily dose now used in LUCIDITY reduced Level 2 events by 53% and Level 3 events by 66% against the medical nutrition therapy-only run-in baseline. Avexitide was generally well tolerated across prior studies.
The FDA has granted avexitide Breakthrough Therapy designation for post-bariatric hypoglycemia, and management anticipates a potential 2027 launch if the drug is approved. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) held $250.8 million in cash, cash equivalents, and short-term investments as of June 30. Based on its current operating plans, Amylyx expects that amount to provide a cash runway into 2028, supporting a potential regulatory filing and commercial preparations.
#pharmaceuticals #NASDAQ
LUCIDITY randomized 78 adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery in a 3:2 ratio to receive once-daily avexitide or placebo. The FDA-agreed primary outcome measures the reduction in the composite of Level 2 and Level 3 hypoglycemic events through Week 16. Avexitide is designed to block the exaggerated GLP-1 response that can drive excess insulin secretion and dangerous drops in blood glucose.
The trial is therefore more than another pipeline update. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) currently has no approved product, and avexitide is its most advanced near-term opportunity to rebuild a commercial business. A positive result would validate the company's move into endocrine disease. A miss would return attention to earlier-stage programs that cannot replace a late-stage **** et quickly.
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) enters the readout with supportive early evidence. Amylyx said five earlier Phase 1 and Phase 2 studies produced consistent signals. In a 28-day, open-label Phase 2b crossover study involving 16 patients who had undergone Roux-en-Y gastric bypass or other upper gastrointestinal surgeries, the 90 mg once-daily dose now used in LUCIDITY reduced Level 2 events by 53% and Level 3 events by 66% against the medical nutrition therapy-only run-in baseline. Avexitide was generally well tolerated across prior studies.
The FDA has granted avexitide Breakthrough Therapy designation for post-bariatric hypoglycemia, and management anticipates a potential 2027 launch if the drug is approved. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) held $250.8 million in cash, cash equivalents, and short-term investments as of June 30. Based on its current operating plans, Amylyx expects that amount to provide a cash runway into 2028, supporting a potential regulatory filing and commercial preparations.
#pharmaceuticals #NASDAQ
6 hours ago
BitFuFu Inc. (NASDAQ:FUFU) reported a quarter that exposed the difference between producing more Bitcoin and making more money from it. Second-quarter revenue fell 62.9% year over year to $42.8 million, while a $20.5 million net loss replaced a $47.1 million profit. Yet average hashrate allocated to self-mining rose 47%, helping lift self-mined production 34% to 192 Bitcoin. Shares closed 11% lower at $1.29 on August 17 after the results. For BitFuFu Inc. (NASDAQ:FUFU), the question is whether shifting more computing power toward self-mining creates operating leverage or simply increases its exposure to Bitcoin prices and network difficulty.
The largest hole was cloud mining, historically the company's biggest revenue source. Cloud Mining Solutions revenue plunged 73.6% to $24.9 million. BitFuFu attributed the decline to lower selling prices amid falling Bitcoin prices, weaker market sentiment, and reduced order volumes from existing customers. The company reported net dollar retention of 24.1%, calculated as second-quarter 2026 recurring revenue divided by total second-quarter 2025 Cloud Mining revenue. Equipment sales also fell to zero from $5.2 million. The cloud-mining decline overwhelmed the benefit of BitFuFu Inc. (NASDAQ:FUFU) allocating more hashrate to self-mining.
Self-mining was hardly immune. Revenue declined to $14.0 million from $14.8 million even as production increased. BitFuFu attributed the decline to the combined effect of a 27.5% drop in the average Bitcoin price to $71,600 and higher network difficulty, partially offset by the increased self-mining allocation. Network difficulty reduced daily Bitcoin earned per terahash by 9.7%. Cost of revenue reached $43.7 million, exceeding total revenue. A $16.9 million net fair-value loss on digital ***** ets and digital-asset receivables or payables significantly affected company-defined adjusted EBITDA, a non-GAAP measure, which was negative $18.4 million. BitFuFu Inc. (NASDAQ:FUFU) therefore suffered from both weaker operating economics and an adverse accounting swing.
BitFuFu Inc. (NASDAQ:FUFU) produced more Bitcoin despite the harsher environment, deployed next-generation S21 XP miners, and restored total managed hashrate to approximately 20 EH/s by mid-August from 15.3 EH/s at quarter-end. Hosting and other revenue also rose to $3.9 million from $1.1 million. If Bitcoin prices recover while difficulty and power costs become more favorable, the larger self-mining allocation could turn higher production into a much stronger revenue and earnings response.
#bitfufu #self #NASDAQ #cloud
The largest hole was cloud mining, historically the company's biggest revenue source. Cloud Mining Solutions revenue plunged 73.6% to $24.9 million. BitFuFu attributed the decline to lower selling prices amid falling Bitcoin prices, weaker market sentiment, and reduced order volumes from existing customers. The company reported net dollar retention of 24.1%, calculated as second-quarter 2026 recurring revenue divided by total second-quarter 2025 Cloud Mining revenue. Equipment sales also fell to zero from $5.2 million. The cloud-mining decline overwhelmed the benefit of BitFuFu Inc. (NASDAQ:FUFU) allocating more hashrate to self-mining.
Self-mining was hardly immune. Revenue declined to $14.0 million from $14.8 million even as production increased. BitFuFu attributed the decline to the combined effect of a 27.5% drop in the average Bitcoin price to $71,600 and higher network difficulty, partially offset by the increased self-mining allocation. Network difficulty reduced daily Bitcoin earned per terahash by 9.7%. Cost of revenue reached $43.7 million, exceeding total revenue. A $16.9 million net fair-value loss on digital ***** ets and digital-asset receivables or payables significantly affected company-defined adjusted EBITDA, a non-GAAP measure, which was negative $18.4 million. BitFuFu Inc. (NASDAQ:FUFU) therefore suffered from both weaker operating economics and an adverse accounting swing.
BitFuFu Inc. (NASDAQ:FUFU) produced more Bitcoin despite the harsher environment, deployed next-generation S21 XP miners, and restored total managed hashrate to approximately 20 EH/s by mid-August from 15.3 EH/s at quarter-end. Hosting and other revenue also rose to $3.9 million from $1.1 million. If Bitcoin prices recover while difficulty and power costs become more favorable, the larger self-mining allocation could turn higher production into a much stronger revenue and earnings response.
#bitfufu #self #NASDAQ #cloud
6 hours ago
Home Depot's earnings beat looked great on paper, but **** ysts on the call kept circling one large one-time gain to see if the company's core profitability is really holding up.
Home Depot (HD) stock has struggled over the past twelve months, but its latest earnings report sent shares higher on what looked like a solid beat, with sales up 5.7% for the quarter. When **** ysts got management on the line, however, they weren't focused on the headline numbers. They kept circling back to one central, awkward question: was the company's strong performance real, or was it an illusion created by a large, one-time $685 million tariff refund?
The Margin Math Had a $685 Million Asterisk
The core of the investment case was tested immediately. The market was already questioning whether Home Depot's profitability actually missed expectations once you stripped out the tariff refund. This isn't just an accounting debate; it's a direct challenge to whether the underlying business can handle rising costs. One **** yst framed the worry bluntly, referencing "discussion in the market this morning" about a potential miss if the refund were excluded.
Management's response was direct and numerical. They explained the $685 million refund was about a 145-basis-point gross impact to margin. Of that, roughly 60 basis points offset 'unplanned pressure from fuel, energy and other product input costs,' and another 60 basis points of mix impact from a recent acquisition ate into the rest, leaving a net benefit of about 85 basis points, which flowed through to the quarter's 25-basis-point year-over-year gross margin gain. The argument was that this was a 'market-borne benefit' used to absorb market-borne costs, allowing them to maintain value for customers. It was a confident answer that provided a clear breakdown of the moving parts, rather than a general **** urance.
#refund #market #million #costs
Home Depot (HD) stock has struggled over the past twelve months, but its latest earnings report sent shares higher on what looked like a solid beat, with sales up 5.7% for the quarter. When **** ysts got management on the line, however, they weren't focused on the headline numbers. They kept circling back to one central, awkward question: was the company's strong performance real, or was it an illusion created by a large, one-time $685 million tariff refund?
The Margin Math Had a $685 Million Asterisk
The core of the investment case was tested immediately. The market was already questioning whether Home Depot's profitability actually missed expectations once you stripped out the tariff refund. This isn't just an accounting debate; it's a direct challenge to whether the underlying business can handle rising costs. One **** yst framed the worry bluntly, referencing "discussion in the market this morning" about a potential miss if the refund were excluded.
Management's response was direct and numerical. They explained the $685 million refund was about a 145-basis-point gross impact to margin. Of that, roughly 60 basis points offset 'unplanned pressure from fuel, energy and other product input costs,' and another 60 basis points of mix impact from a recent acquisition ate into the rest, leaving a net benefit of about 85 basis points, which flowed through to the quarter's 25-basis-point year-over-year gross margin gain. The argument was that this was a 'market-borne benefit' used to absorb market-borne costs, allowing them to maintain value for customers. It was a confident answer that provided a clear breakdown of the moving parts, rather than a general **** urance.
#refund #market #million #costs
6 hours ago
On August 13, Ascendis Pharma (NASDAQ:ASND) reported second-quarter results that showed how far its rare disease portfolio has come. Total product revenue roughly doubled from a year earlier to €315 million, and for the first time all three of the company's approved TransCon therapies, SKYTROFA, YORVIPATH and YUVIWEL, were contributing meaningful sales in the same quarter. That combination is what management is leaning on to justify its 2030 revenue ambitions.
YORVIPATH, the hypoparathyroidism treatment, generated €252 million in the quarter and crossed blockbuster level on an annualized basis just two years after its U.S. launch, while reaching patients in more than 35 countries through either commercial sales or named patient access programs. Long-term trial data presented during the quarter showed response rates sustained between 82% and 86% on the combined endpoint, with patients still on therapy at a 95% rate five years after starting.
SKYTROFA, the once-weekly growth hormone therapy, crossed 20,000 unique patient enrollments and remains the best-selling long-acting growth hormone in the US as measured by brand value, contributing €55 million for the quarter. YUVIWEL, the newest of the three, launched commercially in the US during the quarter and brought in €8 million in its first quarter on the market. Enrollment kept climbing after the quarter closed, from more than 170 unique patients through June 30 to more than 220 by the end of July, with more than 65% of those patients already approved for reimbursement. Ascendis also ended the quarter with €812 million in cash and carries no bank debt or convertible debt, giving it room to keep funding these launches without outside financing.
The growth came with a steeper cost base. SG&A expenses rose to €173 million in the quarter from €145 million in the prior quarter, and R&D expenses climbed to €76 million from €59 million, a comparison made sharper by the fact that the prior quarter's figure had been reduced by a one-time €11 million reversal of earlier inventory write-downs. Reported operating profit of €220 million also leaned heavily on a one-time item, a €158 million gain tied to the sale of a PRV. Strip that out and non-IFRS operating profit was €92 million, a 27% margin that better reflects the underlying business. Total revenue of €339 million for the quarter also included €24 million of non-product collaboration revenue, including a €17 million milestone payment tied to TransCon CNP, money that will not repeat every quarter. And while YUVIWEL's early numbers are strong, formal regulatory decisions for the drug in the U.S. and European Union are not expected until the fourth quarter of 2026, meaning current sales are happening ahead of full approval.
#patients #time #transcon
YORVIPATH, the hypoparathyroidism treatment, generated €252 million in the quarter and crossed blockbuster level on an annualized basis just two years after its U.S. launch, while reaching patients in more than 35 countries through either commercial sales or named patient access programs. Long-term trial data presented during the quarter showed response rates sustained between 82% and 86% on the combined endpoint, with patients still on therapy at a 95% rate five years after starting.
SKYTROFA, the once-weekly growth hormone therapy, crossed 20,000 unique patient enrollments and remains the best-selling long-acting growth hormone in the US as measured by brand value, contributing €55 million for the quarter. YUVIWEL, the newest of the three, launched commercially in the US during the quarter and brought in €8 million in its first quarter on the market. Enrollment kept climbing after the quarter closed, from more than 170 unique patients through June 30 to more than 220 by the end of July, with more than 65% of those patients already approved for reimbursement. Ascendis also ended the quarter with €812 million in cash and carries no bank debt or convertible debt, giving it room to keep funding these launches without outside financing.
The growth came with a steeper cost base. SG&A expenses rose to €173 million in the quarter from €145 million in the prior quarter, and R&D expenses climbed to €76 million from €59 million, a comparison made sharper by the fact that the prior quarter's figure had been reduced by a one-time €11 million reversal of earlier inventory write-downs. Reported operating profit of €220 million also leaned heavily on a one-time item, a €158 million gain tied to the sale of a PRV. Strip that out and non-IFRS operating profit was €92 million, a 27% margin that better reflects the underlying business. Total revenue of €339 million for the quarter also included €24 million of non-product collaboration revenue, including a €17 million milestone payment tied to TransCon CNP, money that will not repeat every quarter. And while YUVIWEL's early numbers are strong, formal regulatory decisions for the drug in the U.S. and European Union are not expected until the fourth quarter of 2026, meaning current sales are happening ahead of full approval.
#patients #time #transcon
7 hours ago
Shares of H World Group Limited (NASDAQ:HTHT) jumped 11.3% to $46.61 on August 17 after second-quarter results combined continued growth, a higher outlook, and an aggressive capital-return program. Hotel turnover, which measures room and non-room transaction value across the network, increased 13.2% to RMB30.5 billion, while revenue rose 10.8% to RMB7.1 billion. The company raised its 2026 revenue-growth forecast to 4%-8% from 2%-6% and authorized up to $2.5 billion of dividends and repurchases over three years. For H World Group Limited (NASDAQ:HTHT), the question is whether those returns will come from stronger cash generation or eventually compete with hotel openings and upgrades.
As of June 30, H World Group Limited (NASDAQ:HTHT) operated 13,539 hotels with 1.34 million rooms and had 3,089 unopened hotels in its pipeline. Its China business opened 498 hotels and closed 176 during the quarter. Only one opening was leased and owned, underscoring how expansion is shifting toward managed and franchised properties. Across the group, 93% of rooms operated under those ****** et-light models.
H World Group Limited (NASDAQ:HTHT) ended June with RMB14.2 billion, or $2.1 billion, of cash and equivalents against RMB4.2 billion of debt. Including RMB142 million of restricted cash, net cash totaled RMB10.2 billion. Second-quarter operating cash inflow was RMB3.4 billion. The board also declared an approximately $275 million ordinary dividend, equal to $0.87 per American Depositary Share. The larger plan sets an aggregate three-year ceiling, while leaving the timing and mix of dividends and repurchases to the board.
H World Group Limited (NASDAQ:HTHT) is still expanding, not retreating. Management maintained its 2026 target of 2,200-2,300 gross hotel openings, and nearly every China opening during the quarter used a manachised or franchised structure. Franchisees supply much of the property capital, while H World supplies brands, technology, reservations and operating support.
That structure is already improving the earnings mix. Franchised revenue increased 25.2% to RMB3.6 billion, while H World Group Limited (NASDAQ:HTHT) lifted non-GAAP adjusted EBITDA 20.0% to RMB2.7 billion. Operating margin widened to 31.1% from 27.8%. If that momentum continues, shareholder returns can be funded without sacrificing network growth.
#World #cash #quarter #hotel
As of June 30, H World Group Limited (NASDAQ:HTHT) operated 13,539 hotels with 1.34 million rooms and had 3,089 unopened hotels in its pipeline. Its China business opened 498 hotels and closed 176 during the quarter. Only one opening was leased and owned, underscoring how expansion is shifting toward managed and franchised properties. Across the group, 93% of rooms operated under those ****** et-light models.
H World Group Limited (NASDAQ:HTHT) ended June with RMB14.2 billion, or $2.1 billion, of cash and equivalents against RMB4.2 billion of debt. Including RMB142 million of restricted cash, net cash totaled RMB10.2 billion. Second-quarter operating cash inflow was RMB3.4 billion. The board also declared an approximately $275 million ordinary dividend, equal to $0.87 per American Depositary Share. The larger plan sets an aggregate three-year ceiling, while leaving the timing and mix of dividends and repurchases to the board.
H World Group Limited (NASDAQ:HTHT) is still expanding, not retreating. Management maintained its 2026 target of 2,200-2,300 gross hotel openings, and nearly every China opening during the quarter used a manachised or franchised structure. Franchisees supply much of the property capital, while H World supplies brands, technology, reservations and operating support.
That structure is already improving the earnings mix. Franchised revenue increased 25.2% to RMB3.6 billion, while H World Group Limited (NASDAQ:HTHT) lifted non-GAAP adjusted EBITDA 20.0% to RMB2.7 billion. Operating margin widened to 31.1% from 27.8%. If that momentum continues, shareholder returns can be funded without sacrificing network growth.
#World #cash #quarter #hotel
7 hours ago
On August 13, Ondas (NASDAQ:ONDS) held its second-quarter earnings call, and the numbers explain why the stock has been getting attention. Revenue hit $83.8 million, more than thirteen times what the company generated in the same quarter a year earlier. Management didn't stop at reporting the number. It raised full-year guidance, pointed to a backlog that has grown elevenfold since the start of 2026, and said it now expects to exit the year at a $1 billion annualized revenue run rate. For a company built by stitching together drone and counter-drone technology companies, this was the quarter meant to prove the strategy actually works.
The headline number was revenue of $83.8 million, up 67% sequentially, but the more telling figure is that organic growth, stripping out the effect of acquisitions, ran at approximately 85% year over year. Ondas raised its full-year 2026 revenue target to a range of $525 million to $550 million and guided third-quarter revenue to $140 million to $155 million, which implies roughly 73% sequential growth at the midpoint. If that ramp holds through the fourth quarter, the company expects to finish 2026 at a $1 billion annualized run rate, putting it years ahead of the $1.5 billion target it had set for 2030.
Backlog and demand back up the guidance. Pro forma backlog stood at $757 million on June 30, up 66% sequentially from $457 million at the end of the first quarter, while the two-year strategic pipeline has swelled past $11 billion, more than 2.5 times what it stood in May. New orders kept arriving on top of that: $175 million booked during the quarter itself and roughly $105 million more already captured so far in the third quarter.
The growth isn't just acquisition math, either. Sentrycs, the counter-drone unit, posted pro forma revenue growth of about 298% year over year, 4M's demining and land intelligence business grew 258%, and Airobotics rose 112%. Rotron, added through acquisition, booked $34.2 million of orders in a single quarter against the $25 million of full-year 2026 revenue Ondas had underwritten when it bought the company. The balance sheet backs the ambition: cash and short-term investments reached $1.4 billion, up from $616 million at the end of 2025, leaving room to spend $325 million in the third quarter alone on the DZYNE and Cyberhawk acquisitions. Contract wins add further weight, including $240 million of orders under a $982 million U.S. Army unmanned strike contract awarded to Mistral, a $140 million combat engineering vehicle program for INDO Earth, and a new one-way attack system deal with Israel's Ministry of Defense. The company also added former Mossad Director David Barnea and retired four-star General Charlie Flynn to its leadership and advisory ranks.
#ondas
The headline number was revenue of $83.8 million, up 67% sequentially, but the more telling figure is that organic growth, stripping out the effect of acquisitions, ran at approximately 85% year over year. Ondas raised its full-year 2026 revenue target to a range of $525 million to $550 million and guided third-quarter revenue to $140 million to $155 million, which implies roughly 73% sequential growth at the midpoint. If that ramp holds through the fourth quarter, the company expects to finish 2026 at a $1 billion annualized run rate, putting it years ahead of the $1.5 billion target it had set for 2030.
Backlog and demand back up the guidance. Pro forma backlog stood at $757 million on June 30, up 66% sequentially from $457 million at the end of the first quarter, while the two-year strategic pipeline has swelled past $11 billion, more than 2.5 times what it stood in May. New orders kept arriving on top of that: $175 million booked during the quarter itself and roughly $105 million more already captured so far in the third quarter.
The growth isn't just acquisition math, either. Sentrycs, the counter-drone unit, posted pro forma revenue growth of about 298% year over year, 4M's demining and land intelligence business grew 258%, and Airobotics rose 112%. Rotron, added through acquisition, booked $34.2 million of orders in a single quarter against the $25 million of full-year 2026 revenue Ondas had underwritten when it bought the company. The balance sheet backs the ambition: cash and short-term investments reached $1.4 billion, up from $616 million at the end of 2025, leaving room to spend $325 million in the third quarter alone on the DZYNE and Cyberhawk acquisitions. Contract wins add further weight, including $240 million of orders under a $982 million U.S. Army unmanned strike contract awarded to Mistral, a $140 million combat engineering vehicle program for INDO Earth, and a new one-way attack system deal with Israel's Ministry of Defense. The company also added former Mossad Director David Barnea and retired four-star General Charlie Flynn to its leadership and advisory ranks.
#ondas
7 hours ago
T. Rowe Price, the Baltimore **** et manager with about $1.9 trillion under management, agreed late Thursday to acquire F/m Investments for an undisclosed sum, adding a fast-growing fixed-income ETF specialist to its lineup.
F/m manages about $19 billion in total, with more than $10 billion of it in 20 ETFs and the rest in separately managed accounts. Modest as that is next to T. Rowe's total AUM, it would more than double the **** ets T. Rowe holds in its own fixed-income ETFs, a corner of the market where the firm has been a minor player despite its size.
T. Rowe currently has 10 U.S.-listed fixed income ETFs with $6.5 billion in them. Across all categories, it has 34 ETFs with almost $33 billion in AUM.
F/m pioneered single-bond ETFs, funds that continuously hold a single Treasury tenor, such as the latest on-the-run 10-year note, giving investors more precise control over their exposure than a fund like the iShares 7-10 Year Treasury Bond ETF (IEF), which holds a range of maturities.
Its flagship is the F/m US Treasury 3 Month Bill ETF (TBIL), which at $7.2 billion accounts for more than 70% of F/m's ETF **** ets and charges 0.15% a year.
Since launching its initial suite of single-bond funds, F/m has kept innovating. It created an ultrashort take on inflation-protected bonds, the F/m Ultrashort Treasury Inflation-Protected Security ETF (RBIL).
It also designed the F/m Compoundr U.S. Aggregate Bond ETF (CPAG), which rotates among broad bond ETFs to sidestep distributions, and therefore taxes, giving investors a way to hold bonds as a diversifier without generating yield.
The firm was also the first to launch a dual-share-class ETF and has filed a first-of-its-kind application for tokenized ETF shares.
For T. Rowe, the acquisition of F/m brings in a focused, methodical issuer whose products are clearly resonating with investors. The firm manages roughly $1.9 trillion in total, but ranks just 29th among US ETF providers.
Buying F/m brings instant scale in fixed-income ETFs and a team with a record of building products investors want, at a moment when T. Rowe's leadership has made growing the ETF business a priority.
The deal is the second acquisition of an ETF manager announced this month. Last week, Goldman Sachs agreed to buy NEOS Investments for up to $2.25 billion, months after closing its roughly $2 billion purchase of Innovator Capital in April.
Together the deals are a part of a wave of consolidation taking place across the $16.3 trillion U.S. ETF industry, as large **** et managers buy their way into the fast growing industry. The T. Rowe transaction is expected to close in early 2027.
Permalink | © Copyright 2026 etf.com. All rights reserved
#treasury #income #year #trillion
F/m manages about $19 billion in total, with more than $10 billion of it in 20 ETFs and the rest in separately managed accounts. Modest as that is next to T. Rowe's total AUM, it would more than double the **** ets T. Rowe holds in its own fixed-income ETFs, a corner of the market where the firm has been a minor player despite its size.
T. Rowe currently has 10 U.S.-listed fixed income ETFs with $6.5 billion in them. Across all categories, it has 34 ETFs with almost $33 billion in AUM.
F/m pioneered single-bond ETFs, funds that continuously hold a single Treasury tenor, such as the latest on-the-run 10-year note, giving investors more precise control over their exposure than a fund like the iShares 7-10 Year Treasury Bond ETF (IEF), which holds a range of maturities.
Its flagship is the F/m US Treasury 3 Month Bill ETF (TBIL), which at $7.2 billion accounts for more than 70% of F/m's ETF **** ets and charges 0.15% a year.
Since launching its initial suite of single-bond funds, F/m has kept innovating. It created an ultrashort take on inflation-protected bonds, the F/m Ultrashort Treasury Inflation-Protected Security ETF (RBIL).
It also designed the F/m Compoundr U.S. Aggregate Bond ETF (CPAG), which rotates among broad bond ETFs to sidestep distributions, and therefore taxes, giving investors a way to hold bonds as a diversifier without generating yield.
The firm was also the first to launch a dual-share-class ETF and has filed a first-of-its-kind application for tokenized ETF shares.
For T. Rowe, the acquisition of F/m brings in a focused, methodical issuer whose products are clearly resonating with investors. The firm manages roughly $1.9 trillion in total, but ranks just 29th among US ETF providers.
Buying F/m brings instant scale in fixed-income ETFs and a team with a record of building products investors want, at a moment when T. Rowe's leadership has made growing the ETF business a priority.
The deal is the second acquisition of an ETF manager announced this month. Last week, Goldman Sachs agreed to buy NEOS Investments for up to $2.25 billion, months after closing its roughly $2 billion purchase of Innovator Capital in April.
Together the deals are a part of a wave of consolidation taking place across the $16.3 trillion U.S. ETF industry, as large **** et managers buy their way into the fast growing industry. The T. Rowe transaction is expected to close in early 2027.
Permalink | © Copyright 2026 etf.com. All rights reserved
#treasury #income #year #trillion
7 hours ago
Richard A. Brooks/Getty Images
Shein is asking some of its existing investors to invest in an initial public offering that is supposed to give them an exit. While it's a welcome development for some, a series of failed attempts to go public means skepticism remains.
Bloomberg reported on Thursday that Chinese investment manager Boyu Capital and UBS ***** et Management are in talks to become cornerstone investors in the online fast-fashion retailer's Hong Kong listing. Shein has set aside at least $400 million of stock for cornerstone investors and is seeking to raise about $2 billion overall at a valuation of $26 billion to $27 billion.
Tencent and General Atlantic are among the other existing investors weighing commitments, according to the report.
Boyu is one of Shein's largest identifiable shareholders, owning Series D and D+ preferred shares at prices implying a value of roughly $815 million, according to Shein's draft IPO prospectus. The Hong Kong firm was founded in 2010 by partners including Alvin Jiang, a grandson of Jiang Zemin, leader of the Chinese Communist Party from 1989 to 2002.
#kong #jiang
Shein is asking some of its existing investors to invest in an initial public offering that is supposed to give them an exit. While it's a welcome development for some, a series of failed attempts to go public means skepticism remains.
Bloomberg reported on Thursday that Chinese investment manager Boyu Capital and UBS ***** et Management are in talks to become cornerstone investors in the online fast-fashion retailer's Hong Kong listing. Shein has set aside at least $400 million of stock for cornerstone investors and is seeking to raise about $2 billion overall at a valuation of $26 billion to $27 billion.
Tencent and General Atlantic are among the other existing investors weighing commitments, according to the report.
Boyu is one of Shein's largest identifiable shareholders, owning Series D and D+ preferred shares at prices implying a value of roughly $815 million, according to Shein's draft IPO prospectus. The Hong Kong firm was founded in 2010 by partners including Alvin Jiang, a grandson of Jiang Zemin, leader of the Chinese Communist Party from 1989 to 2002.
#kong #jiang
7 hours ago
On August 13, Karyopharm Therapeutics (NASDAQ:KPTI) held its second-quarter earnings call, and the story split cleanly in two. The company laid out a myelofibrosis combination therapy with data strong enough to earn an accelerated approval pathway from the FDA, alongside a cash position that funds operations only into September. A $15.8 million loan payment lands September 10, and management admitted that paying it without new financing could trip a liquidity covenant and trigger default. Investors are being asked to weigh a genuinely differentiated drug against a genuinely short clock.
The bull case rests on selinexor paired with ruxolitinib, which Karyopharm plans to submit for FDA review this month under the Accelerated Approval Pathway for myelofibrosis. The Phase III SENTRY study found statistically significant, rapid, deep, and sustained spleen volume reductions, along with a preliminary overall survival signal and hints of disease modification. At week 24, the combination nearly doubled the spleen response rate versus ruxolitinib alone, with responses showing up as early as week 12 and holding through week 36 across patient subgroups. Even when ruxolitinib was dosed below 15 milligrams a day, the combination produced SVR35 rates as high as 50%, compared with zero for ruxolitinib alone, suggesting doctors could trim ruxolitinib without losing efficacy.
The overall survival hazard ratio at the time of the topline ******* ysis was 0.43. If cleared, this would be the first approved combination therapy in frontline myelofibrosis, a disease affecting roughly 20,000 people in the US with about 4,000 newly treated each year and no combination option on the market. Karyopharm pegs the peak US revenue opportunity at up to $1 billion and plans to lean on the commercial infrastructure it already runs for XPOVIO, including its KaryForward patient support program, to move quickly if approved. On the existing business, XPOVIO generated $30.8 million in U.S. net product revenue in the quarter, with demand holding roughly flat from a year earlier even as the treatment landscape gets more crowded.
The financial picture is where the caution belongs. Total revenue fell to $33.4 million from $37.9 million a year earlier, largely because Menarini's reimbursement of development costs ended in late 2025, a roughly $6.5 million swing. Net loss widened to $67 million from $37.3 million, and while some of that reflects non-cash mark-to-market adjustments tied to the company's financing structure, the cash balance tells its own story: $65.4 million in cash, equivalents, and investments at quarter end. Management said that funds current plans only through September 2026. A $15.8 million term loan payment is due September 10, and if it goes out without additional financing or a lender waiver, cash would fall below the $10 million minimum liquidity covenant, an event of default.
#september #cash #karyopharm #myelofibrosis
The bull case rests on selinexor paired with ruxolitinib, which Karyopharm plans to submit for FDA review this month under the Accelerated Approval Pathway for myelofibrosis. The Phase III SENTRY study found statistically significant, rapid, deep, and sustained spleen volume reductions, along with a preliminary overall survival signal and hints of disease modification. At week 24, the combination nearly doubled the spleen response rate versus ruxolitinib alone, with responses showing up as early as week 12 and holding through week 36 across patient subgroups. Even when ruxolitinib was dosed below 15 milligrams a day, the combination produced SVR35 rates as high as 50%, compared with zero for ruxolitinib alone, suggesting doctors could trim ruxolitinib without losing efficacy.
The overall survival hazard ratio at the time of the topline ******* ysis was 0.43. If cleared, this would be the first approved combination therapy in frontline myelofibrosis, a disease affecting roughly 20,000 people in the US with about 4,000 newly treated each year and no combination option on the market. Karyopharm pegs the peak US revenue opportunity at up to $1 billion and plans to lean on the commercial infrastructure it already runs for XPOVIO, including its KaryForward patient support program, to move quickly if approved. On the existing business, XPOVIO generated $30.8 million in U.S. net product revenue in the quarter, with demand holding roughly flat from a year earlier even as the treatment landscape gets more crowded.
The financial picture is where the caution belongs. Total revenue fell to $33.4 million from $37.9 million a year earlier, largely because Menarini's reimbursement of development costs ended in late 2025, a roughly $6.5 million swing. Net loss widened to $67 million from $37.3 million, and while some of that reflects non-cash mark-to-market adjustments tied to the company's financing structure, the cash balance tells its own story: $65.4 million in cash, equivalents, and investments at quarter end. Management said that funds current plans only through September 2026. A $15.8 million term loan payment is due September 10, and if it goes out without additional financing or a lender waiver, cash would fall below the $10 million minimum liquidity covenant, an event of default.
#september #cash #karyopharm #myelofibrosis
7 hours ago
On August 13, Cellebrite (NASDAQ:CLBT) named a new chief executive and trimmed its full-year outlook on the same morning. Shiven Ramji stepped in as CEO effective that day, replacing Tom Hogan, while the company lowered its 2026 revenue and ARR targets after several large government deals slipped past the quarter. Management highlighted positive growth drivers during the call, including its first major FedRAMP contract for Guardian and early customer adoption for its newly launched AI platform, Genesis.
Underneath the disappointment, the underlying numbers still point up. Annual recurring revenue grew 21% year over year to $508 million, and revenue reached $131 million, up 16%, with subscription revenue making up 91% of that total. Gross margin was 86%, and adjusted EBITDA reached $31.8 million (a 24% margin). Cellebrite also raised its full-year adjusted EBITDA target to $153 million to $159 million.
Growth is also getting broader. Defense and intelligence ARR jumped 25%, and U.S. federal government growth accelerated into the mid-teens after sitting flat at the end of 2025. Asia Pacific was the standout region, growing 29%. The newer products are starting to matter too. Cellebrite closed its first major FedRAMP deal for Guardian with a long-standing US federal customer, an initial seven-figure order that was nearly 35 times the average annual spend of roughly $50,000 by a typical state or local agency. Genesis, a consumption-based AI product that launched June 10, 2026, pulled in about $400,000 in ARR within its first weeks and had already landed more than half a dozen customers by the end of the quarter, with trials expanding into the UK, Australia and Europe.
The reasons for the guidance cut are just as concrete. A handful of large transactions that management expected to close in the second quarter instead slipped beyond it, partly because of new administrative and procurement requirements tied to Cellebrite's foreign entity status with US federal and European government customers. At the same time, the shift toward the company's Insights product is not generating as much extra pricing and footprint expansion as expected, especially among US state and local government customers, where growth slowed to just below 20% from the mid-20% range a year earlier. Without newer product offerings such as Advanced Unlocks and Guardian Investigate, management said state and local government growth would have been in the mid-teens.
#Growth #quarter
Underneath the disappointment, the underlying numbers still point up. Annual recurring revenue grew 21% year over year to $508 million, and revenue reached $131 million, up 16%, with subscription revenue making up 91% of that total. Gross margin was 86%, and adjusted EBITDA reached $31.8 million (a 24% margin). Cellebrite also raised its full-year adjusted EBITDA target to $153 million to $159 million.
Growth is also getting broader. Defense and intelligence ARR jumped 25%, and U.S. federal government growth accelerated into the mid-teens after sitting flat at the end of 2025. Asia Pacific was the standout region, growing 29%. The newer products are starting to matter too. Cellebrite closed its first major FedRAMP deal for Guardian with a long-standing US federal customer, an initial seven-figure order that was nearly 35 times the average annual spend of roughly $50,000 by a typical state or local agency. Genesis, a consumption-based AI product that launched June 10, 2026, pulled in about $400,000 in ARR within its first weeks and had already landed more than half a dozen customers by the end of the quarter, with trials expanding into the UK, Australia and Europe.
The reasons for the guidance cut are just as concrete. A handful of large transactions that management expected to close in the second quarter instead slipped beyond it, partly because of new administrative and procurement requirements tied to Cellebrite's foreign entity status with US federal and European government customers. At the same time, the shift toward the company's Insights product is not generating as much extra pricing and footprint expansion as expected, especially among US state and local government customers, where growth slowed to just below 20% from the mid-20% range a year earlier. Without newer product offerings such as Advanced Unlocks and Guardian Investigate, management said state and local government growth would have been in the mid-teens.
#Growth #quarter
7 hours ago
LOS ANGELES, CALIFORNIA - FEBRUARY 28: Morgan Frost #16 of the Calgary Flames skates with the puck against Quinton Byfield #55 of the Los Angeles Kings during the third period at Crypto.com Arena on February 28, 2026 in Los Angeles, California. (Photo by Ric Tapia/Getty Images) Getty
The Montreal Canadiens have spent much of the summer resisting the urge to force another major move.
A fresh trade possibility could give general manager Kent Hughes a way to strengthen the middle of his lineup without chasing one of the biggest names on the market.
Ken MacMillan of The Hockey Writers named the Calgary Flames as one of three teams Montreal could trade with during the preseason on Aug. 22, singling out Morgan Frost as an ideal fit for the Canadiens.
Frost is coming off a career year in Calgary.
#california #morgan #montreal #canadiens
The Montreal Canadiens have spent much of the summer resisting the urge to force another major move.
A fresh trade possibility could give general manager Kent Hughes a way to strengthen the middle of his lineup without chasing one of the biggest names on the market.
Ken MacMillan of The Hockey Writers named the Calgary Flames as one of three teams Montreal could trade with during the preseason on Aug. 22, singling out Morgan Frost as an ideal fit for the Canadiens.
Frost is coming off a career year in Calgary.
#california #morgan #montreal #canadiens
7 hours ago
Our ****** ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Delivered 18th consecutive quarter of traffic growth and 15th consecutive quarter of market share gains, driven by a value proposition that resonates across all income cohorts, though the vast majority of growth continues to be driven by higher income members.
Achieved a new milestone of 8.5 million members, with membership fee income (MFI) growing nearly 10% year-over-year due to strong acquisition and higher-tier penetration.
Utilized favorable fuel market dynamics and strong volume growth to generate outsized fuel profits, which were partially reinvested into member value and price gaps.
Implemented a systematic Category Management Process (CMP) to optimize ****** ortments, resulting in strong performance in beverages, Active Nutrition, and renovated Home categories.
#driven #value #members
Delivered 18th consecutive quarter of traffic growth and 15th consecutive quarter of market share gains, driven by a value proposition that resonates across all income cohorts, though the vast majority of growth continues to be driven by higher income members.
Achieved a new milestone of 8.5 million members, with membership fee income (MFI) growing nearly 10% year-over-year due to strong acquisition and higher-tier penetration.
Utilized favorable fuel market dynamics and strong volume growth to generate outsized fuel profits, which were partially reinvested into member value and price gaps.
Implemented a systematic Category Management Process (CMP) to optimize ****** ortments, resulting in strong performance in beverages, Active Nutrition, and renovated Home categories.
#driven #value #members
8 hours ago
NVIDIA Corporation (NASDAQ:NVDA) is weighing a step that would have seemed unthinkable a year ago: shipping its next-generation Rubin Ultra GPU with less memory than originally promised. According to The Information, the company has been testing at least three versions with reduced high-bandwidth memory, some as low as 192GB to 256GB, well below the 1 terabyte Jensen Huang originally announced.
Meanwhile, rival Advanced Micro Devices, Inc. (NASDAQ:AMD) is pushing ahead with its own AI system, Helios, which ships to customers including Microsoft, Meta, OpenAI, and Oracle later this year. AMD says it already has the memory it needs.
Both chipmakers are racing to build next-generation AI systems just as the entire industry runs into a severe memory shortage.
That raises a real question: is NVIDIA Corporation (NASDAQ:NVDA) genuinely caught off guard on supply, or is AMD's confidence about locking up memory the bigger story here?
Even with less memory, Nvidia still controls more than 95% of the data center GPU market. Spreading scarce memory across more GPUs lets NVIDIA Corporation (NASDAQ:NVDA) protect production volume, and a lower-memory version could become a genuinely cheaper option that broadens its customer base. Nothing is finalized yet, and Rubin Ultra doesn't ship until late 2027, giving Nvidia time to adjust. The company has also struck a $500 billion partnership with SK Hynix's parent company to co-develop future memory technology, a move Nvidia VP Raj Mirpuri said it would "help us secure a stable supply."
#NASDAQ #corporation #nvda #next
Meanwhile, rival Advanced Micro Devices, Inc. (NASDAQ:AMD) is pushing ahead with its own AI system, Helios, which ships to customers including Microsoft, Meta, OpenAI, and Oracle later this year. AMD says it already has the memory it needs.
Both chipmakers are racing to build next-generation AI systems just as the entire industry runs into a severe memory shortage.
That raises a real question: is NVIDIA Corporation (NASDAQ:NVDA) genuinely caught off guard on supply, or is AMD's confidence about locking up memory the bigger story here?
Even with less memory, Nvidia still controls more than 95% of the data center GPU market. Spreading scarce memory across more GPUs lets NVIDIA Corporation (NASDAQ:NVDA) protect production volume, and a lower-memory version could become a genuinely cheaper option that broadens its customer base. Nothing is finalized yet, and Rubin Ultra doesn't ship until late 2027, giving Nvidia time to adjust. The company has also struck a $500 billion partnership with SK Hynix's parent company to co-develop future memory technology, a move Nvidia VP Raj Mirpuri said it would "help us secure a stable supply."
#NASDAQ #corporation #nvda #next
9 hours ago
On August 5, Meta Platforms, Inc. (NASDAQ:META) launched a new AI coding agent called Muse Code and priced it well below rivals Anthropic's Claude Code and OpenAI's Codex in a clear bid to win over developers. The release landed the same week. Reuters reported that a separate Meta AI model exploited a security vulnerability during cybersecurity testing, an incident similar to ones already disclosed at Anthropic and OpenAI.
Muse Code comes in two pricing tiers: one matches Meta Platforms, Inc. (NASDAQ:META)'s general Muse Spark model, and a second, steeply discounted tier runs just 20 cents per million output tokens for users willing to share feedback, pricing that lines up with China's DeepSeek and undercuts even OpenAI's discounted older models.
Meta AI chief Alexandr **** put it simply, saying the pricing can be an incredibly good option for a lot of workflows, especially from a cost perspective. The stakes here are real. Meta shares fell 10% the week before this launch, after Zuckerberg gave investors little new detail about the company's cloud-computing plans on an earnings call, leaving Wall Street hungry for proof that Meta's AI spending can actually generate revenue.
Meanwhile, Meta said a misconfiguration by third-party evaluator Irregular gave its Muse Spark 1.1 model unintended internet access during testing. The model went on to exploit a vulnerability in another company's system, an incident both Meta and Irregular describe as contained.
Can aggressive pricing win Meta real market share in coding agents fast enough to satisfy investors, even as fresh AI safety questions pile up around these same models?
#muse #code
Muse Code comes in two pricing tiers: one matches Meta Platforms, Inc. (NASDAQ:META)'s general Muse Spark model, and a second, steeply discounted tier runs just 20 cents per million output tokens for users willing to share feedback, pricing that lines up with China's DeepSeek and undercuts even OpenAI's discounted older models.
Meta AI chief Alexandr **** put it simply, saying the pricing can be an incredibly good option for a lot of workflows, especially from a cost perspective. The stakes here are real. Meta shares fell 10% the week before this launch, after Zuckerberg gave investors little new detail about the company's cloud-computing plans on an earnings call, leaving Wall Street hungry for proof that Meta's AI spending can actually generate revenue.
Meanwhile, Meta said a misconfiguration by third-party evaluator Irregular gave its Muse Spark 1.1 model unintended internet access during testing. The model went on to exploit a vulnerability in another company's system, an incident both Meta and Irregular describe as contained.
Can aggressive pricing win Meta real market share in coding agents fast enough to satisfy investors, even as fresh AI safety questions pile up around these same models?
#muse #code
9 hours ago
The Houston Rockets have had players donning a total of 52 different jersey numbers (and have one not part of any numerical series for Houston ****** istant coach and general manager Carroll Dawson) since their founding at the start of the 1967-68 season, worn by just under 500 players in the course of Rockets history.
To honor all of the players who wore those numbers over the decades, Rockets Wire is covering the entire history of jersey numbers and the players who wore them since the founding of the team all those years ago right up to the present day.
With seven of those jerseys now retired to honor some of the greatest Rockets of all time to wear those jerseys, there is a lot of history to cover.
And for today's article, we will continue with the first of two who wore the No. 28, center Tarik Black. After ending his college career at Kansas, Black went unselected in the 2014 NBA Draft, Black signed with the Houston Rockets instead.
The Memphis, Tennessee native played the first 25 games of his pro career with Houston in his first stint with the team, coming to an end when he was cut at the end of 2014. He also played for the Los Angeles Lakers before returning to the Rockets in 2017 for his final season in the league.
#rockets #numbers #first
To honor all of the players who wore those numbers over the decades, Rockets Wire is covering the entire history of jersey numbers and the players who wore them since the founding of the team all those years ago right up to the present day.
With seven of those jerseys now retired to honor some of the greatest Rockets of all time to wear those jerseys, there is a lot of history to cover.
And for today's article, we will continue with the first of two who wore the No. 28, center Tarik Black. After ending his college career at Kansas, Black went unselected in the 2014 NBA Draft, Black signed with the Houston Rockets instead.
The Memphis, Tennessee native played the first 25 games of his pro career with Houston in his first stint with the team, coming to an end when he was cut at the end of 2014. He also played for the Los Angeles Lakers before returning to the Rockets in 2017 for his final season in the league.
#rockets #numbers #first
10 hours ago
HSBC Holdings plc (NYSE:HSBC) posted a stronger-than-expected first-half profit this week and resumed its share buyback program. UBS Group AG (NYSE:UBS) posted its own profit beat, but it's facing a $125 million fine from U.S. regulators. Hedge funds had already been quietly trimming their UBS positions before that fine even became public.
Europe's biggest banks are having a strong earnings season, but HSBC is telling the cleaner story of the two. Its profit beat came from wealth management growth, a resumed buyback, and a raised outlook for net interest income. On the other hand, UBS Group AG (NYSE:UBS) beat estimates too, but its win comes with a catch, i.e., a $125 million fine from U.S. regulators for repeated anti-money-laundering failures, alongside a hedge fund base that had already been quietly pulling back heading into the quarter.
This makes you wonder: does a clean earnings beat matter more to investors than a resolved regulatory problem? Or does UBS's history as a "repeat offender" cast a longer shadow over its recovery than HSBC Holdings plc (NYSE:HSBC)'s cleaner quarter?
First-half profit rose 23% to $19.5 billion, beating the $18.9 billion ***** ysts expected. HSBC Holdings plc (NYSE:HSBC) resumed its buyback with a plan of up to $1 billion after pausing for three quarters to fund its Hang Seng Bank takeover. It also raised its guidance for net interest income to exceed $46 billion. Wealth revenue grew 18%. The bank added 640,000 new clients in the first half. Corporate and institutional banking is now HSBC's biggest income source, generating a third of first-half profit. The bank has more than 70 IPOs lined up across Asia.
However, Citi flagged that the new $1 billion buyback came in well below the $2.2 billion investors expected, raising the question of whether HSBC is permanently scaling back its repurchases. The stock dropped from its own record high right after the earnings release. HSBC is also still exiting several businesses, including its Singapore insurance unit, Egypt retail banking, and Australian mortgages, which is a sign of ongoing restructuring rather than pure growth.
#buyback
Europe's biggest banks are having a strong earnings season, but HSBC is telling the cleaner story of the two. Its profit beat came from wealth management growth, a resumed buyback, and a raised outlook for net interest income. On the other hand, UBS Group AG (NYSE:UBS) beat estimates too, but its win comes with a catch, i.e., a $125 million fine from U.S. regulators for repeated anti-money-laundering failures, alongside a hedge fund base that had already been quietly pulling back heading into the quarter.
This makes you wonder: does a clean earnings beat matter more to investors than a resolved regulatory problem? Or does UBS's history as a "repeat offender" cast a longer shadow over its recovery than HSBC Holdings plc (NYSE:HSBC)'s cleaner quarter?
First-half profit rose 23% to $19.5 billion, beating the $18.9 billion ***** ysts expected. HSBC Holdings plc (NYSE:HSBC) resumed its buyback with a plan of up to $1 billion after pausing for three quarters to fund its Hang Seng Bank takeover. It also raised its guidance for net interest income to exceed $46 billion. Wealth revenue grew 18%. The bank added 640,000 new clients in the first half. Corporate and institutional banking is now HSBC's biggest income source, generating a third of first-half profit. The bank has more than 70 IPOs lined up across Asia.
However, Citi flagged that the new $1 billion buyback came in well below the $2.2 billion investors expected, raising the question of whether HSBC is permanently scaling back its repurchases. The stock dropped from its own record high right after the earnings release. HSBC is also still exiting several businesses, including its Singapore insurance unit, Egypt retail banking, and Australian mortgages, which is a sign of ongoing restructuring rather than pure growth.
#buyback
11 hours ago
Morgan Fairchild showed off a different side of her style as she stepped out in Los Angeles wearing a cool rock-chick ensemble.
The 76-year-old actress was dressed in an oversized black T-shirt bearing a colourful Godzilla graphic as she walked through the city.
Morgan teamed the statement top with slim black trousers and coordinating sock-style sneakers, creating a far more casual look than the polished gowns and tailored outfits she generally wears for public appearances.
Morgan was spotted out and about in LA (@ GC Images)
Her signature platinum-blonde hair was worn loose with plenty of volume, while dark eye makeup provided the finishing touch to her monochrome outfit. The actress accessorised with a gold watch and bracelets.
#style #actress #different
The 76-year-old actress was dressed in an oversized black T-shirt bearing a colourful Godzilla graphic as she walked through the city.
Morgan teamed the statement top with slim black trousers and coordinating sock-style sneakers, creating a far more casual look than the polished gowns and tailored outfits she generally wears for public appearances.
Morgan was spotted out and about in LA (@ GC Images)
Her signature platinum-blonde hair was worn loose with plenty of volume, while dark eye makeup provided the finishing touch to her monochrome outfit. The actress accessorised with a gold watch and bracelets.
#style #actress #different
